India Welcomes its First Inhalable Insulin by Cipla
Cipla’s launch of Afrezza, India’s first inhalable insulin, marks a transformative milestone in diabetes care within the country. Developed by MannKind Corporation, Afrezza provides a needle-free, rapid-acting insulin alternative that is inhaled through a compact device, offering convenience and reducing the barriers posed by injectable therapies. This innovative approach targets adults with type 1 and … Read more